S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
S33005 displayed marked affinity for native, rat, and cloned human serotonin (5-HT) transporters (SERT) and less pronounced affinity for norepinephrine (NE) transporters (NET), while its affinity at dopamine (DA) transporters and >50 other sites was negligible. Reuptake of 5-HT and (less potently) NE into cerebral synaptosomes was inhibited by S33005, whereas DA reuptake was little affected. In vivo, S33005 prevented depletion of cerebral pools of 5-HT by parachloroamphetamine. Furthermore, it decreased electrical activity of raphe-localized serotonergic neurones, an action abolished by the 5-HT1A antagonist WAY100,635. At higher doses, S33005 blocked firing of locus ceruleus-localized adrenergic neurones, an action abolished by the alpha2-adrenergic antagonist idazoxan. In contrast, S33005 did not inhibit ventrotegmental dopaminergic neurones. In frontal cortex of freely moving rats, S33005 dose dependently elevated dialysate levels of 5-HT, NE, and DA. In hippocampus, levels of 5-HT and NE were similarly elevated, while in nucleus accumbens and striatum, levels of 5-HT were increased whereas DA was unaffected. Upon chronic (2 weeks) administration, basal levels of NE were elevated in frontal cortex and, therein, 5-HT2A receptor density was decreased. Comparative studies with clinically used antidepressants showed that venlafaxine possessed a profile similar to S33005 but was less potent. Clomipramine likewise interacted with SERTs and NETs but also with several other receptors types, while citalopram and reboxetine were preferential ligands of SERTs and NETs, respectively. In conclusion, S33005 interacts potently with SERTs and, less markedly, with NETs. It enhances extracellular levels of 5-HT and NE throughout corticolimbic structures and selectively elevates dialysis levels of DA in frontal cortex versus subcortical regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., & Sigg, E. B. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90769-0 · Cited by 374 · cited 1×
“b-ARs (Muth et al., 1986; Schweizer et al., 1997; Nalepa et al., 1998), an observation confirmed herein, and extended to S33005.”
Role of norepinephrine in the pathophysiology and treatment of mood disorders
Ressler, K. J., & Nemeroff, C. B. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00127-4 · Cited by 307
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302 · cited 1×
“This dual activity is likewise displayed by the cyclohexanol derivative, venlafaxine, which lacks the undesirable histaminergic, muscarinic, and a1-AR antagonist properties of clomipramine and other tricyclic agents (Muth et al., 1991; Schweizer et al., 1997; Harvey et al., 2000).”
Prefrontal Cortical Dysfunction in Depression Determined by Wisconsin Card Sorting Test Performance
Merriam, E. P., Thase, M. E., Haas, G. L., Keshavan, M. S., & Sweeney, J. A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.780 · Cited by 278
Sánchez, C., & Meier, E. (1997) · Psychopharmacology · doi:10.1007/s002130050181 · Cited by 255
The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185 · cited 1×
“Clinical studies have demonstrated the efficacy of venlafaxine in major depressive states, including resistant and, probably, bipolar patients (Amsterdam, 1998; Poirier and Boyer, 1999).”
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183
Cited by
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Self-citationA brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Self-citationStahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Antidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392
Metadata
- Authors
- Millan, M. J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J.-M., Auclair, A., & Peglion, J.-L.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2001-08
- Volume
- 298
- Issue
- 2
- Pages
- 565-580
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2158720692
- Cited by
- 146
- References
- 11
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine. https://app.cochat.ai/papers/10.1016/s0022-3565(24)29415-5
- The paper
- Millan, M. J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J.-M., Auclair, A., & Peglion, J.-L. (2001). S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(24)29415-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.